DHG Pharmaceutical JSCSTC:DHG -1.48%77 Piotroski F-Score is 8 as of Jun. 24, 2026, which is 33% above its 10-year median of 6.00. GuruFocus rates STC:DHG with a GF Score™ of 77/100 and a GF Value™ of ₫113,344.20 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 981 Drug Manufacturers companies, DHG Pharmaceutical JSC ranks better than 98.37% on this metric.
Good Sign:
Piotroski F-Score is 8, indicates a very healthy situation.
The zones of discrimination were as such:
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
DHG Pharmaceutical JSC has an F-score of 8. It is a good or high score, which usually indicates a very healthy situation.
The historical rank and industry rank for DHG Pharmaceutical JSC's Piotroski F-Score or its related term are showing as below:
STC:DHG'
s Piotroski F-Score Range Over the Past 10 Years
Min: 3 Med: 6 Max: 9
Current: 8
During the past 13 years, the highest Piotroski F-Score of DHG Pharmaceutical JSC was 9. The lowest was 3. And the median was 6.
The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.
He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.
He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.
What he found was something that exceeded his most optimistic expectations.
Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.
Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).
Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.
DHG Pharmaceutical JSC Piotroski F-Score Related Terms
DHG Pharmaceutical JSC Piotroski F-Score Historical Data
* Premium members only.
The historical data trend for DHG Pharmaceutical JSC's Piotroski F-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, DHG Pharmaceutical JSC's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DHG Pharmaceutical JSC Piotroski F-Score vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, DHG Pharmaceutical JSC's Piotroski F-Score distribution charts can be found below:
* The bar in red indicates where DHG Pharmaceutical JSC's Piotroski F-Score falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
This Year (Mar26) TTM:
Last Year (Mar25) TTM:
Net Income was 236894.865 + 209644.276 + 184797.127 + 315677.281 = ₫947,014 Mil. Cash Flow from Operations was 368343.206 + 56677.854 + 436429.442 + 5959.732 = ₫867,410 Mil. Revenue was 1184237.014 + 1145709.088 + 1742471.806 + 1198100.183 = ₫5,270,518 Mil. Gross Profit was 585226.355 + 561669.299 + 798089.923 + 600227.549 = ₫2,545,213 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was
(5755508.307 + 5495044.458 + 5600956.966 + 5173881.629 + 5245728.16) / 5 = ₫5454223.904 Mil. Total Assets at the begining of this year (Mar25) was ₫5,755,508 Mil. Long-Term Debt & Capital Lease Obligation was ₫0 Mil. Total Current Assets was ₫3,991,624 Mil. Total Current Liabilities was ₫731,251 Mil.
Net Income was 192484.446 + 156014.719 + 208192.211 + 266239.849 = ₫822,931 Mil.
Revenue was 1105832.177 + 1061838.685 + 1458678.268 + 1194544.777 = ₫4,820,894 Mil. Gross Profit was 497621.013 + 461251.784 + 666396.135 + 567386.132 = ₫2,192,655 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was
(6201306.253 + 6155169.131 + 6253272.867 + 5959243.276 + 5755508.307) / 5 = ₫6064899.9668 Mil. Total Assets at the begining of last year (Mar24) was ₫6,201,306 Mil. Long-Term Debt & Capital Lease Obligation was ₫0 Mil. Total Current Assets was ₫4,399,551 Mil. Total Current Liabilities was ₫1,320,608 Mil.
*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.
Profitability
Question 1. Return on Assets (ROA)
Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
DHG Pharmaceutical JSC's current Net Income (TTM) was 947,014.
==> Positive ==> Score 1.
Question 2. Cash Flow Return on Assets (CFROA)
Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
DHG Pharmaceutical JSC's current Cash Flow from Operations (TTM) was 867,410.
==> Positive ==> Score 1.
Question 3. Change in Return on Assets
Compare this year's return on assets (1) to last year's return on assets.
DHG Pharmaceutical JSC's return on assets of this year was 0.16454038. DHG Pharmaceutical JSC's return on assets of last year was 0.13270288.
==> This year is higher. ==> Score 1.
Question 4. Quality of Earnings (Accrual)
Compare Cash flow return on assets (2) to return on assets (1)
DHG Pharmaceutical JSC's gearing of this year was 0. DHG Pharmaceutical JSC's gearing of last year was 0.
==> This year is lower or equal to last year. ==> Score 1.
Question 6. Change in Working Capital (Liquidity)
Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.
Score 1 if this year's current ratio is higher, 0 if it's lower
DHG Pharmaceutical JSC's current ratio of this year was 5.45862331. DHG Pharmaceutical JSC's current ratio of last year was 3.33145968.
==> This year's current ratio is higher. ==> Score 1.
Question 7. Change in Shares in Issue
Compare the number of shares in issue this year, to the number in issue last year.
Score 0 if there is larger number of shares in issue this year, 1 otherwise.
DHG Pharmaceutical JSC's number of shares in issue this year was 130.746. DHG Pharmaceutical JSC's number of shares in issue last year was 130.746.
==> There is smaller number of shares in issue this year, or the same. ==> Score 1.
Efficiency
Question 8. Change in Gross Margin
Compare this year's gross margin (Gross Profit divided by sales) to last year's.
Score 1 if this year's gross margin is higher, 0 if it's lower.
DHG Pharmaceutical JSC's gross margin of this year was 0.48291517. DHG Pharmaceutical JSC's gross margin of last year was 0.45482334.
==> This year's gross margin is higher. ==> Score 1.
Question 9. Change in asset turnover
Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.
Score 1 if this year's asset turnover ratio is higher, 0 if it's lower
DHG Pharmaceutical JSC's asset turnover of this year was 0.9157346. DHG Pharmaceutical JSC's asset turnover of last year was 0.77739975.
==> This year's asset turnover is higher. ==> Score 1.
Evaluation
Piotroski F-Score
=
Que. 1
+
Que. 2
+
Que. 3
+
Que. 4
+
Que. 5
+
Que. 6
+
Que. 7
+
Que. 8
+
Que. 9
=
1
+
1
+
1
+
0
+
1
+
1
+
1
+
1
+
1
=
8
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
DHG Pharmaceutical JSC has an F-score of 8. It is a good or high score, which usually indicates a very healthy situation.
DHG Pharmaceutical JSC (STC:DHG) has a Piotroski F-Score of 8 as of Jun. 24, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on DHG Pharmaceutical JSC and its competitors. This is 33% above median its historical median of 6.00. Over the past decade, DHG Pharmaceutical JSC's Piotroski F-Score has ranged from 3.00 to 9.00. According to the industry distribution chart, DHG Pharmaceutical JSC ranks #16 out of 981 companies in the Drug Manufacturers industry, placing it in the top 1.6%.
Is DHG Pharmaceutical JSC's Piotroski F-Score too high?
DHG Pharmaceutical JSC's current Piotroski F-Score of 8 is 33% above median its 10-year median of 6.00. Over the past 10 years, this metric has ranged from a low of 3.00 to a high of 9.00. The Drug Manufacturers industry median Piotroski F-Score is 5.00. DHG Pharmaceutical JSC's value of 8 is 60% above this industry median. Based on the distribution chart, DHG Pharmaceutical JSC ranks #16 out of 981 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, DHG Pharmaceutical JSC has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does DHG Pharmaceutical JSC's Piotroski F-Score compare to ZTS?
According to the Drug Manufacturers industry distribution chart, DHG Pharmaceutical JSC ranks #16 out of 981 companies for Piotroski F-Score. This places DHG Pharmaceutical JSC in the top 2% of its industry — outperforming the majority of peers. The industry median Piotroski F-Score is 5.00. DHG Pharmaceutical JSC's value of 8 is 60% above this benchmark. Historically, DHG Pharmaceutical JSC's own Piotroski F-Score has ranged from 3.00 to 9.00 over the past decade. While the company's 10-year median is 6.00 vs. the industry median of 5.00, DHG Pharmaceutical JSC has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Drug Manufacturers company?
The median Piotroski F-Score among Drug Manufacturers companies is 5.00, based on 981 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. DHG Pharmaceutical JSC's current Piotroski F-Score of 8 is 60% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on DHG Pharmaceutical JSC and its competitors. For the Drug Manufacturers industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. DHG Pharmaceutical JSC's current Piotroski F-Score is 8, which is 33% above median its own 10-year median of 6.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DHG Pharmaceutical JSC stock overvalued right now?
Based on GuruFocus' analysis, DHG Pharmaceutical JSC (STC:DHG) is currently considered Modestly Undervalued. The stock's GF Value™ is ₫113,344.20, compared to a current price of ₫93,300.00 — trading 17.7% below its estimated fair value. The current Piotroski F-Score is 8, which is 33% above median its 10-year median of 6.00 and 60% above the Drug Manufacturers industry median of 5.00. DHG Pharmaceutical JSC's overall GF Score™ is 77/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For DHG Pharmaceutical JSC (STC:DHG), the current Piotroski F-Score is 8 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is DHG Pharmaceutical JSC (STC:DHG) Overvalued in 2026?
Based on GuruFocus' analysis, DHG Pharmaceutical JSC stock appears to be undervalued.
The current stock price of ₫93,300.00 is trading 17.7% below its estimated GF Value™ of ₫113,344.20.
GuruFocus considers DHG Pharmaceutical JSC to be Modestly Undervalued.
Key valuation signals for STC:DHG:
Piotroski F-Score: 8 (33% above median its 10-year median of 6.00)
GF Value™: ₫113,344.20 vs. price of ₫93,300.00 (17.7% below fair value)
Industry Position: 60% above the Drug Manufacturers median (#16 of 981)
No single metric tells the full story. See the STC:DHG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
DHG Pharmaceutical JSC produces and trades in pharmaceutical products. It provides various pharmaceutical products in the areas of antibiotics, antifungals, and antiparasitics; analgesics and antipyretics; ear-nose-throat, cough, and asthma; ophthalmic and nervous system; muscular and osteoarticular; digestive; hepatic; cardiovascular and diabetic; vitamins and minerals; and dermal and beauty care.
77GF Score
Get the complete analysis for STC:DHG
Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STC:DHG has been successfully added to your 
